US-based health technology company Sophia Genetics has partnered with Microsoft and NVIDIA to leverage their technology and genomics expertise to launch a whole genome sequencing (WGS) analytics solution.
The genome sequencing solution is expected to be available by the end of the year and will be hosted on Microsoft Azure and powered by NVIDIA’s scalable genomics analysis software suite, Parabricks.
The entire genome sequencing analytics solution uses SOPhiA DDM, an AI and cloud-based software-as-a-service platform. The technology analyzes genomic data alongside other relevant data points, including diagnostic details, imaging, pathology and medical assessments, to provide more actionable insights into disease and medicine.
“Leveraging the powerful technologies and capabilities provided by Microsoft Azure and NVIDIA, we are working to deliver accurate, scalable and rapid insights across multiple modalities, helping to benefit our customers and, ultimately, of patients, especially those living with rare inherited disorders,” said Abhimanyu Verma, chief technology officer at SOPhiA GENETICS.
“We are confident that our new WGS application will help provide an answer to existing customer needs and accelerate research, diagnosis and treatment planning worldwide.”
The use of AI to accelerate data analysis as part of drug discovery has been an area of interest in recent years. GlobalData predicts AI to be a major driver of medical device innovation. The AI market generated roughly $93 billion in sales last year, according to GlobalData analysis.
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive advantage.
Company Profile – free sample
Your download email will arrive shortly
We are confident in the unique quality of our company profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the form below
From GlobalData
NVIDIA has been a big contributor to this trend and has announced multiple drug discovery deals with pharmaceutical companies. Earlier this year, the company partnered with Amgen to build AI models to analyze human data sets for drug targets and biomarker discovery, facilitating diagnostics for disease progression and regression.
In March, NVIDIA partnered with Microsoft to bring together the global reach and advanced expertise of Azure with NVIDIA’s DGX Cloud and Clara computing platforms to drive innovation and improve patient outcomes. The partnership aims to strengthen clinical research and care delivery using image-based AI diagnostic technology through Microsoft and NVIDIA platforms.
In February, SOPhiA partnered with AstraZeneca to expand the homologous recombination deficiency test for ovarian cancer across Spain. The company had also partnered with GE HealthCare to enable personalized treatment for cancer patients.
#SOPhiA #Genetics #partners #Microsoft #NVIDIA #genome #sequencing
Image Source : www.medicaldevice-network.com